(ROSG) (ROSG) Stock Price, News & Analysis

Company Overview

Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies, such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $0.42 to $0.44
• 50-Day Range: $0.43 to $0.43
• 52-Week Range: $0.23 to $2.75
• Volume: 169,599 shs
• Average Volume: 81,512 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ROSG Stock Analysis - Frequently Asked Questions

How were (ROSG)'s earnings last quarter?

(ROSG) (NASDAQ:ROSG) announced its earnings results on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.02. The medical research company earned $2.60 million during the quarter, compared to the consensus estimate of $3.36 million.

What other stocks do shareholders of (ROSG) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (ROSG) investors own include Agenus (AGEN), Bausch Health Cos (BHC), Endocyte (ECYT), Intercept Pharmaceuticals (ICPT), BIOLASE (BIOL), Eyepoint Pharmaceuticals (EYPT) and (SCMP) (SCMP).

Company Calendar

• Last Earnings: 5/19/2016
• Today: 7/02/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ROSG
• CIK: 1362959
• Web: www.rosettagenomics.com
• Phone: 972732220700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A